drugset / Trial / NCT03329209

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

NCT03329209

Phase 1 Completed 16 enrolled Takeda
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.

Timeline

Start
2018-03-05
Primary completion
2018-07-26
Completion
2018-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vedolizumab Monoclonal antibody 300 mg Intravenous